Skip to main content
Log in

Impact of regional copayment policy on selective serotonin reuptake inhibitor (SSRI) consumption and expenditure in Italy

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The continuous growth of antidepressant consumption and expenditure, especially for selective serotonin reuptake inhibitors (SSRIs), has led to the adoption of several policy measures directed toward cost control in Western countries. In Italy, copayment policies have been heterogeneously introduced at a regional level as part of a strategy designed to reduce drug consumption. The aim of our study was to evaluate whether regional copayment policies have affected trends in the consumption of and expenditure for SSRIs from 2001 to 2007.

Methods

The consumption of SSRIs was measured in terms of defined daily doses per 1,000 inhabitants (DDD/1000) per day from May 2001 to December 2007. Time trends in consumption and expenditure before and after the introduction of copayment policies were examined using segmented regression analysis of interrupted time-series, adjusting for seasonal components. The study was conducted for 17 regions, nine of which had implemented a copayment policy.

Results

The overall consumption of SSRIs in Italy increased during the study period, from a monthly consumption of 12.85 DDD/1000 per day in May 2001 to 23.40 DDD/1000 per day in December 2007. The average monthly increase in SSRI use was 0.82 % in regions with a copayment policy versus 0.77 % in regions without a copayment policy (P = 0.329). According to the multivariable analysis, copayment was associated with a 1 % reduction in the monthly growth rate of SSRI consumption (P  = 0.01). The impact of copayment on expenditure was statistically significant (P  < 0.005) on both the level and the trend, even though the estimate of the effect was negligible.

Conclusions

The implementation of copayment policies in Italy affected both the use and expenditure of SSRIs between 2001 and 2007 to only to a minor extent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatry 184:386–392. doi:10.1192/bjp. 184.5.386

    Article  PubMed  CAS  Google Scholar 

  2. Murray CJL, Lopez AD (1996) The global burden of disease and injury series, volume 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press, Cambridge

    Google Scholar 

  3. World Health Organization (2004) The global burden of disease: 2004 update. Available at: http://www.who.int/entity/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed 1 July 2012

  4. OECD (2009) Health at a Glance 2009: OECD indicators. OECD Publishing, Paris. doi: 10.1787/health_glance-2009-en. http://www.oecd-ilibrary.org/docserver/download/fulltext/8109111e.pdf?expires=1337072474&id=id&accname=guest&checksum=2FE8066C18AA1BE2924D9F59C915A78F. Accessed 1 July 2012

  5. Meredith LS, Branstrom RB, Azocar F, Fikes R, Ettner SL (2011) A collaborative approach to identifying effective incentives for mental health clinicians to improve depression care in a large managed behavioral healthcare organization. Adm Policy Ment Health 38:193–202. doi:10.1007/s10488-010-0313-0

    Article  PubMed  Google Scholar 

  6. Lacasse JR, Leo J (2006) Questionable advertising of psychotropic medications and disease mongering. PLoS Med 3(7):e321. doi:10.1371/journal.pmed.0030321

    Article  PubMed  Google Scholar 

  7. Gruppo di lavoro OsMed (2003) L’uso dei farmaci in Italia. Rapporto nazionale anno 2002. Il Pensiero Scientifico Editore, Roma [OsMed Working Team. The drug utilisation in Italy, National Reports 2002]. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/111.93135.1150790141602c1dc.pdf. Accessed 1 July 2012

  8. Gruppo di lavoro OsMed (2008) L’uso dei farmaci in Italia. Rapporto nazionale anno 2007. Roma: Il Pensiero Scientifico Editore, Roma. [OsMed Working Team. The drug utilisation in Italy, National Reports 2007]. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/rapporto_osmed_2007_0.pdf. Accessed 1 July 2012

  9. Percudani M, Barbui C, Fortino I, Petrovich L (2004) Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord 83(2–3):169–75. doi:10.1016/j.jad.2004.07.005

    Article  PubMed  Google Scholar 

  10. Trifirò G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, Caputi AP, Arcoraci V, UVEC group (2007) Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004. Pharmacoepidemiol Drug Saf 16(5):552–9. doi:10.1002/pds.1303

    Article  PubMed  Google Scholar 

  11. Dunn JD, Cannon HC, Mitchell MP, Curtiss FR (2006) Utilization and Drug Cost Outcomes of a Step-Therapy Edit for Generic Antidepressants in a HMO in an Integrated Health System. J Manag Care Pharm 12(4):294–302

    PubMed  Google Scholar 

  12. Hodgkin D, Horgan CM, Garnick DW, Len Merrick E, Volpe-Vartanian J (2007) Management of access to branded psychotropic medication in private health plans. Clin Ther 29:371–380. doi:10.1016/j.clinthera.2007.02.011

    Article  PubMed  Google Scholar 

  13. Wang PS, Patrick AR, Dormuth CR, Avorn J, Maclure M, Canning CF, Schneeweiss S (2008) The impact of cost-sharing on antidepressants use among older adults in British Columbia. Psychiatr Serv 59:377–383. doi:10.1176/appi.ps.59.4.377

    Article  PubMed  Google Scholar 

  14. Fattore G, Torbica A (2005) Health service benefit catalogues in Europe. Country Report: Italy. HealthBASKET Project. Available at: http://www.ehma.org/files/WP_6_HealthBASKETSP21_CT_2004_501588_D15_Italy.pdf. Accessed 15 Sept 2012

  15. Poluzzi E, Motola D, Silvani C, De Ponti F, Vaccheri A, Montanaro M (2004) Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. Eur J Clin Pharmacol 59(11):825–31. doi:10.1007/s00228-003-0692-1

    Article  PubMed  Google Scholar 

  16. Torbica A, Fattore G (2005) The “Essential Levels of Care” in Italy: when being explicit serves the devolution of powers. Eur J Health Econom 6[Suppl 1]:46-52. doi:10.1007/s10198-005-0318-x

  17. Fattore G, Jommi C (2008) The last decade of Italian pharmaceutical policy: instability or consolidation? Pharmacoeconomics 26(1):5–15

    Article  PubMed  Google Scholar 

  18. Mapelli V, Lucioni C (2003) Spending on pharmaceuticals in Italy: macro constraints with local autonomy. Value Health 6[Suppl 1]:S31–45. doi:10.1046/j.1524-4733.6.s1.4.x

    Article  PubMed  Google Scholar 

  19. Fiorio CV, Siciliani L (2010) Co-payments and the demand for pharmaceuticals: evidence from Italy. Econ Model 27:835–41. doi:10.1016/j.econmod.2009.07.019

    Article  Google Scholar 

  20. WHO Collaborating Centre for Drug Statistics Methodology (2010) Guidelines for ATC classification and DDD assignment 2011. Available at: http://www.whocc.no/filearchive/publications/2011guidelines.pdf. Accessed 15 Sept 2012

  21. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27(4):299–309. doi:10.1046/j.1365-2710.2002.00430.x

    Article  PubMed  CAS  Google Scholar 

  22. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsey C, Oxman AD, Sturm H, Kosters JP, Vernby A (2008) Pharmaceutical policies: effects of cap and co-payment on rational drug use (Review). Cochrane Database Syst Rev 23(1):CD007017

    Google Scholar 

  23. Hosmer W, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New York

    Book  Google Scholar 

  24. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML (2005) Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care 11(10):621–628

    PubMed  Google Scholar 

  25. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, Landsman PB, Teutsch SM (2004) Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291(19):2344–2350. doi:10.1001/jama.291.19.2344

    Article  PubMed  CAS  Google Scholar 

  26. Ong M, Catalano R, Harting T (2003) A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clin Ther 25(4):1262–1275. doi:10.1016/S0149-2918(03)80082-6

    Article  PubMed  Google Scholar 

  27. Goldman DP, Joyce GF, Zheng Y (2007) Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298(1):61–69. doi:10.1001/jama.298.1.61

    Article  PubMed  CAS  Google Scholar 

  28. Stevenson FA, Greenfield SM, Jones M, Nayak A, Bradley CP (1999) GPs' perceptions of patient influence on prescribing. Fam Pract 16:255–61

    Article  PubMed  CAS  Google Scholar 

  29. Sleath B, Shih YC (2003) Sociological influences on antidepressant prescribing. Soc Sci Med 56(6):1335–44. doi:10.1016/S0277-9536(02)00132-6

    Article  PubMed  Google Scholar 

  30. Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG (2004) Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 42(12):1176–85

    Article  PubMed  Google Scholar 

  31. Dewa CS, Hoch JS, Goering P (2008) Previous out-of-pocket drug expenditures and patterns of antidepressant use among workers receiving depression-related disability benefits. Healthc Policy 4(2):e149–e166

    PubMed  Google Scholar 

  32. Pichetti S, Sorasith C, Sermet C (2011) Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time series analysis for France 1998-2010. Health Policy 102(2–3):159–169. doi:10.1016/j.healthpol.2011.07.001

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gianfranco Damiani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Damiani, G., Federico, B., Silvestrini, G. et al. Impact of regional copayment policy on selective serotonin reuptake inhibitor (SSRI) consumption and expenditure in Italy. Eur J Clin Pharmacol 69, 957–963 (2013). https://doi.org/10.1007/s00228-012-1422-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1422-3

Keywords

Navigation